Nomura Securities Reiterates Buy on Synchrony Financial (SYF) Following Better-Than-Expected Payout
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
Synchrony Financial (SYF): Capital Plan Larger Than Expected - Jefferies
July 8, 2016 8:28 AM EDTJefferies analyst, John Hecht, reiterated his Buy rating on Synchrony Financial (NYSE: SYF) after announcing its capital plan for the next 4 quarters. The total payout of ~$1.38B, nearly 60% of forecasted CY16 income, is modestly ahead of expectations.
The total annual dividend of $0.52 compares... More
BTIG Affirms Synchrony Financial (SYF) at 'Buy' as New Catalyst Appears
July 8, 2016 8:10 AM EDTBTIG affirms Synchrony Financial (NYSE: SYF) with a Buy rating and $42 price target following the company's announcement... More
After-Hours Stock Movers 07/07: (CUDA) (GPS) (SYF) Higher; (JUNO) (KITE) (PSMT) Lower (more...)
July 7, 2016 6:00 PM EDTToday's After-Hours Movers
Juno Therapeutics' (NASDAQ: JUNO) 27.2% LOWER; announced that it has received notice from the U.S. Food and Drug Administration (FDA) that a clinical hold has been placed on the Phase II clinical trial of JCAR015 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia (r/r ALL), known as the ROCKET trial. The clinical hold was initiated after two patient deaths last... More
Synchrony Financial (SYF) Declares $0.13 Quarterly Dividend; $952M Buyback
July 7, 2016 5:30 PM EDTSynchrony Financial (NYSE: SYF) declared a quarterly dividend of $0.13 per share, or $0.52 annualized.
The dividend will be payable on August 25, 2016, to stockholders of record on August 12, 2016, with an ex-dividend date of August 10, 2016.
The annual yield on the dividend is 2... More
